Handle and cartridge system for medical interventions

Information

  • Patent Grant
  • 11801041
  • Patent Number
    11,801,041
  • Date Filed
    Friday, July 23, 2021
    2 years ago
  • Date Issued
    Tuesday, October 31, 2023
    6 months ago
Abstract
An apparatus for transferring mechanical energy in a handle to a cartridge to manipulate tissue or anatomical structures within the body of a human or animal subject for the purpose of treating diseases or disorders. The handle and cartridge contain safety interlocks.
Description
BACKGROUND OF THE INVENTION

The present invention relates generally to medical devices, and more particularly to medical device systems including a handle and replaceable cartridge. In such systems, mechanical energy in the handle is transferred into the cartridge to manipulate tissue or anatomical structures within the body of a human or animal subject for the purpose of treating diseases or disorders.


Benign Prostatic Hyperplasia (BPH) is one of the most common medical conditions that affect men, especially elderly men. It has been reported that, in the United States, more than half of all men have histopathologic evidence of BPH by age 60 and, by age 85, approximately 9 out of 10 men suffer from the condition. Moreover, the incidence and prevalence of BPH are expected to increase as the average age of the population in developed countries increases.


The prostate gland enlarges throughout a man's life. In some men, the prostatic capsule around the prostate gland may prevent the prostate gland from enlarging further. This causes the inner region of the prostate gland to squeeze the urethra. This pressure on the urethra increases resistance to urine flow through the region of the urethra enclosed by the prostate. Thus, the urinary bladder has to exert more pressure to force urine through the increased resistance of the urethra. Chronic over-exertion causes the muscular walls of the urinary bladder to remodel and become stiffer. This combination of increased urethral resistance to urine flow and stiffness and hypertrophy of urinary bladder walls leads to a variety of lower urinary tract symptoms (LUTS) that may severely reduce the patient's quality of life. These symptoms include weak or intermittent urine flow while urinating, straining when urinating, hesitation before urine flow starts, feeling that the bladder has not emptied completely even after urination, dribbling at the end of urination or leakage afterward, increased frequency of urination particularly at night, and an urgent need to urinate.


In addition to patients with BPH, LUTS may also be present in patients with prostate cancer, prostate infections, and chronic use of certain medications (e.g. ephedrine, pseudoephedrine, phenylpropanolamine, antihistamines such as diphenhydramine, chlorpheniramine etc.) that cause urinary retention especially in men with prostate enlargement.


Although BPH is rarely life threatening, it can lead to numerous clinical conditions including urinary retention, renal insufficiency, recurrent urinary tract infection, incontinence, hematuria, and bladder stones.


In developed countries, a large percentage of the patient population undergoes treatment for BPH symptoms. It has been estimated that by the age of 80 years, approximately 25% of the male population of the United States will have undergone some form of BPH treatment. At present, the available treatment options for BPH include watchful waiting, medications (phytotherapy and prescription medications), surgery, and minimally invasive procedures.


For patients who choose the watchful waiting option, no immediate treatment is provided to the patient, but the patient undergoes regular exams to monitor progression of the disease. This is usually done on patients that have minimal symptoms that are not especially bothersome.


Surgical procedures for treating BPH symptoms include Transurethal Resection of the Prostate (TURP), Transurethral Electrovaporization of the Prostate (TVP), Transurethral Incision of the Prostate (TUIP), Laser Prostatectomy and Open Prostatectomy.


Minimally invasive procedures for treating BPH symptoms include Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA), Interstitial Laser Coagulation (ILC), and Prostatic Stents.


Many current methods of treating BPH carry a high risk of adverse effects. These methods and devices either require general or spinal anesthesia or have potential adverse effects that dictate that the procedures be performed in a surgical operating room followed by a hospital stay for the patient. The methods of treating BPH that carry a lower risk of adverse effects are also associated with a lower reduction in the symptom score. While several of these procedures can be conducted with local analgesia in an office setting, the patient does not experience immediate relief and in fact often experiences worse symptoms for weeks after the procedure until the body begins to heal. Additionally, many device approaches require a urethral catheter placed in the bladder, in some cases for weeks. In some cases, catheterization is indicated because the therapy actually causes obstruction during a period of time post-operatively, and in other cases it is indicated because of post-operative bleeding and potentially occlusive clot formation. While drug therapies are easy to administer, the results are suboptimal, take significant time to take effect, and often entail undesired side effects.


New devices and methods have been developed for various procedures to lift, compress, support, reposition, ablate, or otherwise alter prostatic tissue in a discrete procedure or in combination with treating BPH. Such devices and methods are disclosed in U.S. Pat. Nos. 7,645,286; 7,758,594; 7,766,923; 7,905,889; 7,951,158; 8,007,503; 8,157,815; 8,216,254; 8,333,776; 8,343,187; 8,394,110; 8,425,535; 8,663,243; 8,715,239; 8,715,298; 8,900,252; 8,936,609; 8,939,996; 9,320,511; 9,549,739; 10,105,132; and 10,299,780 which are hereby incorporated by reference herein in their entireties.


There remains a need for mechanical designs and systems to reliably, repeatably, and efficiently transfer energy from the handle to the cartridge of such devices. The present disclosure addresses these needs.


BRIEF SUMMARY OF THE INVENTION

Aspects of the present invention are directed towards mechanical designs and configurations for transferring mechanical energy from a handle to a cartridge for manipulating tissues and anatomical or other structures within the body of a human or animal subject for the purpose of treating diseases or disorders.


In one aspect, a cartridge includes a slidable cutter block connected to a slidable pusher block via an extension spring, wherein the cutter block and the pusher block are configured to slide in a linear within a body of the cartridge. The cartridge also includes a pivotable implant actuator within the body of the cartridge and engaged with the pusher block such that the implant actuator prevents the pusher block from sliding when the implant actuator is in a first position. A spring is in an extended position exerting a force tending to draw the cutter block and the pusher block toward each other. The cartridge includes a knob that moves from an unlocked position to a locked position such that the locked position secures the cartridge to the handle. The cartridge includes a pusher safety tab on the knob configured to engage the implant actuator when the knob is in the unlocked position such that the implant actuator cannot pivot while so engaged. The pusher safety tab on the knob is configured to disengage the implant actuator when the knob is in the locked position and allow the implant actuator to pivot. The cartridge includes a cutter pawl within the body of the cartridge and between the cutter block and the pusher block. The cutter pawl has an engaged position with the cutter block such that the cutter pawl prevents the cutter block from sliding towards the pusher block and a disengaged position with the cutter block such that the cutter pawl allows the cutter block to slide towards the pusher block. The pusher block is configured to slide into contact with the cutter pawl and cause the cutter pawl to pivot out of engagement with the cutter block. The cartridge includes an indicator window on a cover of the body of the cartridge. The indicator window indicates the position of the cutter block. The indicator window is configured to provide access to slide the cutter block. The cartridge includes an access window on the knob that provides access to the cutter pawl to allow the cutter pawl to be moved from the engaged position to the disengaged position without the pusher block contacting the cutter pawl.


In another aspect, a cartridge includes a cartridge body coupled to a shaft assembly having a long axis with a distal portion of the shaft assembly having a lumen running through the distal portion. The lumen has a lumen radius of curvature defined by the curving of the lumen as it runs in a first direction parallel to the long axis to run in a second direction transverse to the long axis. A needle assembly is slidably disposed within the shaft assembly and the cartridge body and having a needle distal portion such that the needle distal portion is configured to exit the shaft assembly from an exit port at which the lumen terminates. The needle distal portion has a needle radius of curvature defined by the curving of the needle as it runs in a first direction parallel to the long axis to run in a second direction transverse to the long axis, where the lumen radius of curvature and the needle radius of curvature are different. The cartridge includes a cutout on the shaft assembly configured to allow at least part of the needle distal portion to flex through the cutout. The cartridge includes an additional cutout on the shaft assembly configured to allow at least part of the needle distal portion to flex through the additional cutout. The cartridge includes a distal lumen wall configured with a wall radius of curvature that is at a tangent to a desired exit trajectory of the needle distal portion.


A system that includes a handle and a cartridge has a cam wheel within the handle and coupled to a trigger assembly included in the handle. A wheel actuator is coupled to the cam wheel such that a feature on the cam wheel is configured to cause the wheel actuator to pivot in a first direction when the feature contacts the wheel actuator. The wheel actuator has a flexure that is engaged when the wheel actuator pivots in the first direction and causes the wheel actuator to pivot in a second direction opposite the first direction when the feature no longer contacts the wheel actuator. The system includes a slidable pusher block and an implant actuator each within the cartridge. The implant actuator is engaged with the pusher block to prevent the pusher block from sliding. The wheel actuator disengages the implant actuator from the pusher block when the wheel actuator pivots in the first direction.


A system that includes a handle and a cartridge has a trigger assembly included in the handle and a lock tab on the trigger assembly configured to enter a cartridge bay of the handle when the trigger is in a working position such that a cartridge cannot be secured within the cartridge bay when the lock tab is at least partially within the cartridge bay. The system includes a lock surface on the cartridge configured to be engaged by the lock tab such that the cartridge cannot be removed from the cartridge bay when the trigger is in the working position. The cartridge can be removed from the cartridge bay when the trigger is in an initial position.


The system delivers an implant formed of a distal anchor component, a suture portion, and a proximal anchor component. The system has a pusher block configured to push the proximal anchor component onto the suture portion and a cutter block configured to cut the suture portion.


Other features and advantages of embodiments of the present invention will become apparent from the following description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, certain principles of the invention.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS


FIG. 1 is a perspective view of one embodiment of a system, including a handle and cartridge, for treating benign prostatic hyperplasia.



FIG. 2A is a perspective view of a handle of one embodiment of a system for treating benign prostatic hyperplasia in which the cartridge has been removed.



FIG. 2B is a perspective view of a cartridge removed from a handle of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 3 is a perspective view of one embodiment of an anchor assembly.



FIG. 4A is an isometric view of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 4B is an isometric view of a needle assembly that is contained within a cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 5A is a side view of a portion of a distal tip component of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 5B is an isometric, cross-sectioned view of a distal tip component of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 6A is a side view of a portion of the distal end of a handle and cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 6B is a bottom view of a portion of the distal end of a handle and cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 7A is a perspective, sectional view of a distal portion of a cartridge of another embodiment of a system for treating benign prostatic hyperplasia.



FIG. 7B is a perspective, sectional view of a distal portion of a cartridge of another embodiment of a system for treating benign prostatic hyperplasia.



FIG. 7C is a perspective, sectional view of a distal portion of a cartridge of another embodiment of a system for treating benign prostatic hyperplasia.



FIG. 8 is a perspective, cutaway view of a distal portion of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 9 is an exploded, isometric view of a handle of a system for treating benign prostatic hyperplasia.



FIG. 10 is an exploded, isometric view of one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 11A is a view of the left side of a cam wheel within one embodiment of a handle of a system for treating benign prostatic hyperplasia.



FIG. 11B is a view of the right side of a cam wheel within one embodiment of a handle of a system for treating benign prostatic hyperplasia.



FIG. 12A is a view of the left side of a cam wheel and certain other mechanical features within one embodiment of a handle and cartridge of a system for treating benign prostatic hyperplasia.



FIG. 12B is a view of the left side of a cam wheel and certain other mechanical features within one embodiment of a handle and cartridge of a system for treating benign prostatic hyperplasia.



FIG. 13A is a side view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 13B is a side view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 14 is a side view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 15A is an exploded, top view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 15B is an exploded, perspective view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 16A is a perspective view of a portion of a handle of one embodiment of a system for treating benign prostatic hyperplasia in which the cartridge has been removed.



FIG. 16B is a side view of a portion of a handle of one embodiment of a system for treating benign prostatic hyperplasia in which the cartridge has been removed.



FIG. 17 is a side view of a portion of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 18A is a perspective view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 18B is a side view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 19A is a side view of a portion of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 19B is a side view of a portion of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 19C is a perspective view of a cartridge cover of one embodiment of a system for treating benign prostatic hyperplasia.



FIG. 20A is an exploded perspective view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.



FIG. 20B is a side view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia.





DETAILED DESCRIPTION OF THE INVENTION

Generally, embodiments of the system of the present disclosure include mechanical designs and configurations for transferring mechanical energy from a handle to a cartridge for manipulating tissues and anatomical or other structures within the body of a human or animal subject for the purpose of treating diseases or disorders. The handle and cartridge cooperate to deliver an implant, or anchor assembly, within tissue. The cartridge is configured to carry the components of an anchor assembly. Multiple cartridges may be used with a single handle such that, during a procedure on an individual subject, multiple anchor assemblies may be deployed within tissue using that single handle.


Turning now to the figures, which are provided by way of example and not limitation, FIG. 1 is a perspective view of one embodiment of a system 1, including a handle 100 and a cartridge 200, for treating benign prostatic hyperplasia. The handle 100 includes sources of mechanical energy that are transferred to the cartridge 200 to deploy the anchor assembly contained within the cartridge 200. The handle 100 is configured such that the energy can be restored to these mechanical energy sources while the first cartridge is being used and/or prior to the insertion of a second cartridge. The handle 100 is designed to reliably deliver energy to multiple cartridges in sequence before a new handle is required. The multiple uses of the handle 100 places unique constraints on the mechanical features of the handle 100 to facilitate the reliable, repeatable transfer of energy from the handle to the cartridge.



FIG. 2A is a perspective view of a handle 100 and FIG. 2B is a perspective view of a cartridge 200 of one embodiment of a system for treating benign prostatic hyperplasia. FIGS. 2A and 2B show the handle 100 and the cartridge 200 disengaged from one another. The handle 100 includes a cartridge bay 101 into which the cartridge 200 can be securely inserted. The cartridge 200 includes a cartridge body 201 that can be positioned to securely engage the cartridge 200 in the cartridge bay 101 of the handle 100. The handle 100 includes a scope tube 102, which is configured to accommodate an endoscopic instrument within a lumen of the scope tube 102. The scope tube 102 facilitates visualization of a treatment site when the system is used to deploy anchor assemblies to tissue. The cartridge 200 includes a shaft assembly 202, which includes parts of other assemblies (such as a needle assembly 210, a suture assembly 220, and a cutter assembly 230 described in further detail herein). The scope tube 102 and the shaft assembly 202 are configured to couple together when the handle 100 and cartridge 200 are engaged with one another. Thus, the handle 100 and the cartridge 200 securely engage one another through the interaction of the cartridge bay 101 with the cartridge body 201 and the scope tube 102 with the shaft assembly 202. The cartridge knob 203 can be rotated from an unlocked position to a locked position to secure the coupling between the cartridge 200 and the handle 100.



FIG. 2B depicts a needle distal portion 212 extending from a shaft distal portion 204. The needle assembly 210 is configured to move between a fully retracted position, in which the entire needle assembly is within the shaft assembly 202 and cartridge body 201, to a fully extended position, in which the needle distal portion 212 extends from a shaft distal portion 204. The needle distal portion 212 contains components of the anchor assembly that is delivered to tissue.



FIG. 3 is a perspective view of one embodiment of an anchor assembly. In an unconstrained configuration, the distal anchor component 70 includes a head portion 72 which is generally orthogonally oriented with respect to a tail portion 74. While housed in the needle distal portion 212 and prior to deployment at a target area, the distal anchor component 70 is constrained to a generally straight configuration, only subsequently assuming the unconstrained (i.e., orthogonally oriented) configuration upon deployment from the needle assembly 210.


In certain embodiments, the distal anchor component 70 is formed from a nitinol base stock that is generally tubular and can be shape-set to include the orthogonally oriented configuration of the head portion 72 with respect to the tail portion 74. A suture 78 is attached to the distal anchor component 70. In one embodiment, a polyethylene terephthalate (PET) suture portion 78 is thermoformed onto locking features in the distal anchor component 70. The distal anchor component 70 may be locally heated to re-flow the suture onto the end of the distal anchor component 70 and into cutouts on the distal anchor component 70. The distal anchor component 70 may be attached to the suture portion 78 through any of several known techniques for bonding a PET material to a nitinol material.


In one embodiment, a mid-section 80 of the distal anchor component 70 provides a structural transition from the head portion 72 to the tail portion 74 and has a portion of a side wall removed in the area of mid-section 80. A further portion of the side wall is removed to define a connector section 82 of the tail portion 74 which extends from the mid-section 80. In one embodiment, this connector section 82 includes a bend that creates the orthogonally oriented configuration. Thus, in its pre-implanted form, the anchor assembly can include a distal anchor component 70 whose initial engagement with a suture portion 78 is generally coaxial.


Still referring to FIG. 3, in one embodiment the proximal anchor component 84 includes prongs 96 that grip the suture portion 78. The interior structure of the prongs 96 functions to disrupt the surface of the suture portion 78, both pressing into the suture portion 78 and compressing the suture portion 78 between the prongs 96. A tab 98 can extend from one or more of the prongs 96 to help create secure engagement between the proximal anchor component 84 and the suture portion 78.


In certain embodiments, the proximal anchor component 84 is present in the shaft assembly 202 in a configuration that is separate and disconnected from the distal anchor component 70 and the suture portion 78, which are engaged with each other and contained within the needle assembly 210. After the distal anchor component 70 and the suture portion 78 have been placed within tissue, the proximal anchor component 84 is securely engaged with the suture portion 78 to form the fully assembled anchor assembly. To facilitate engagement of the proximal anchor component 84 with the suture portion 78, the proximal anchor component 84 includes a rigid, generally cylindrical back end 95. This a rigid, generally cylindrical back end 95 can be used to push the proximal anchor component 84 into engagement with the suture 78 via transfer of the mechanical energy in the handle 100.



FIG. 4A is an isometric view of a cartridge 200 of one embodiment of a system for treating benign prostatic hyperplasia and FIG. 4B is an isometric view of a needle assembly 210 that is contained within such a cartridge 200. The needle assembly 210 includes a needle distal portion 210, a needle shaft 212, and a needle proximal portion 216. In one embodiment, the needle distal portion 210 is formed from nitinol and shape-set into a curved configuration in an unconstrained state. The needle assembly 210 is configured to slide along the long axis of the shaft assembly 202 of the cartridge 200. The needle assembly 210 is initially in a fully retracted position, in which the entire needle assembly is within the shaft assembly 202 and the cartridge body 201. When the needle assembly 210 is slid distally along the long axis of the shaft assembly 202 from its initial position, the needle distal portion 212 extends from a shaft distal portion 204 and eventually reaches a fully extended position. The needle assembly 210 can be slid proximally to retract the needle distal portion 212 back to its position within the shaft assembly 202. A significant part of the proximal length of the needle distal portion 212 is capable of assuming a substantially straight configuration when the needle distal portion 212 is within the shaft assembly 202. As described in further detail herein, the needle proximal portion 216 interacts with the mechanisms in the handle to transmit energy from the handle to the needle assembly 210 to deploy and retract the needle distal portion 212.


In certain embodiments, there can be noticeable amounts of friction between the needle assembly 210 and the shaft assembly 202 when the needle assembly 210 slides with respect to the shaft assembly 202. In some cases, the friction between the needle assembly 210 and the shaft assembly 202 can interfere with the ability of the needle distal portion 212 to move through the shaft distal portion 204. In some cases, such friction can slow the velocity of the needle distal portion 212 as it exits the shaft distal portion 204 and thereby compromise the effective treatment of a patient. That is, in the case of treating benign prostatic hyperplasia, the needle distal portion 212 should move into tissue with sufficient velocity such that the distal tip of the needle distal portion 212 can penetrate through the tough tissue capsule that surrounds the prostate gland.


There are various sources for the friction between the needle assembly 210 and the shaft assembly 202 when the needle assembly 210 slides with respect to the shaft assembly 202. For example, discontinuities or imperfections along the inner surfaces of the shaft assembly 202 and/or the outer surface of the needle assembly 210 can increase friction between the needle assembly 210 and the shaft assembly 202. One important source of friction is the restraining force exerted on the needle distal portion 212 to induce it to be substantially straight along a significant part of its proximal length. That is, the shape-set configuration of the needle distal portion 212 includes a pre-determined radius of curvature that the needle distal portion 212 assumes when in an unconstrained state. This pre-determined radius of curvature is designed so that the needle distal portion 212 penetrates tissue at a particular angle (or range of angles) and at a particular position (or range of positions) with respect to the distal exit point of the needle distal portion 212 from the shaft distal portion 204. The method of treating benign prostatic hyperplasia performed by embodiments of the system described herein relies on a generally transverse path of the needle through tissue with respect to the long axis of the shaft assembly 202.


The pre-determined radius of curvature enables the needle distal portion 212 to penetrate tissue along such a generally transverse path. However, as described herein, a significant part of the proximal length of the needle distal portion 212 is constrained to be substantially straight when the needle distal portion 212 is within the shaft distal portion 204. While the needle distal portion 212 is comparatively flexible, constraining the needle distal portion 212 does create multiple points of contact along the inner surface of the shaft assembly 202 and the inner surface of the shaft distal portion 204.



FIG. 5A is a side view of a portion of a distal tip component of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia and FIG. 5B is an isometric, cross-sectioned view of the distal tip component. The shaft distal portion 204 includes a shaft distal portion exit port 205 from which the needle distal portion (not pictured) emerges when the needle distal portion is extended from the shaft distal portion 204. The shaft distal portion exit port 205 is the distal terminus of a shaft distal portion lumen 207. The shaft distal portion lumen 207 has a certain effective radius of curvature as the lumen transitions from running along the long axis of the shaft assembly to running in a direction transverse to the long axis of the shaft assembly. An aspect of that transition is the shaft distal portion interior exit wall 208, which is essentially the distal-most portion of the shaft distal portion lumen 207. Thus, when the needle assembly is present within the shaft assembly, the effective radius of curvature of the shaft distal portion lumen 207 and the shaft distal portion interior exit wall 208 can strongly influence the amount of friction that the needle assembly experiences when slid with respect to the shaft assembly.



FIG. 6A is a side view and FIG. 6B is a bottom view of a portion of the distal end of a handle and cartridge of one embodiment of a system for treating benign prostatic hyperplasia. FIGS. 6A and 6B depict the needle assembly in a retracted position within the shaft assembly 202 and shaft distal portion 204. That is, the needle assembly is being constrained to be substantially straight as compared to its shape-set configuration, which has a radius of curvature that positions the distal tip of the needle in a direction transverse to the long axis of the needle assembly. However, a shaft distal portion cutout 206 provides an opening between the interior and exterior of the shaft distal portion 204 and a portion of the needle distal portion 212 protrudes through the shaft distal portion cutout 206. The shaft distal portion cutout 206 allows at least part of the needle distal portion 212 to flex through a part of the bottom surface of the shaft distal portion 204, which allows the needle distal portion 212 to assume a smaller radius of curvature than would be possible if there were no shaft distal portion cutout 206. That is, the shaft distal portion cutout 206 allows for there to be less constraining force on the needle distal portion 212. The needle distal portion 212 does not contact a hard surface in the interior of the shaft distal portion 204 and this reduces the number of surfaces that the needle distal portion 212 contacts while moving with respect to the shaft distal portion 204. Fewer surface contacts can mean less overall friction during movement. Further, the shaft distal portion cutout 206 can help maintain the preferred exit trajectory of the needle distal portion 212 by accommodating part of the shape-set radius of curvature. In some embodiments, cutouts may be present along other parts of the shaft assembly 202. These cutouts can also reduce the number of surfaces that the needle assembly contacts while moving with respect to the shaft assembly 202.



FIGS. 7A, 7B, and 7C are perspective, sectional views of distal portions of cartridges of various embodiments of a system for treating benign prostatic hyperplasia. These embodiments illustrate various arrangements of the shaft distal portion interior exit wall 208. These embodiments intend to reduce the contact points and/or friction experienced by the needle assembly as it slides with respect to the shaft assembly. In FIG. 7A, the shaft distal portion interior exit wall 208 is configured with a radius of curvature that is at a tangent to the desired exit trajectory of the needle. In FIG. 7B, the shaft distal portion interior exit wall 208 is configured with a straight section where the entire section is angled at a tangent to the desired exit trajectory of the needle. In FIG. 7C, the shaft distal portion interior exit wall 208 is configured with a partial exit wall and a shaft distal portion upper cutout 209 on the upper surface. The shaft distal portion upper cutout 209 is intended to reduce the number of contact points between the shaft distal portion lumen and the needle assembly. Further, the shaft distal portion interior exit wall 208 is formed to minimize the presence of surface discontinuities, such as flash, burrs, or sharp edges.



FIG. 8 is a perspective, cutaway view of a distal portion of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia. FIG. 8 illustrates one embodiment of the configuration of the shaft distal portion lumen 207 as the lumen curves towards the shaft distal portion exit port 205. In this configuration, the curved section of the shaft distal portion lumen 207 includes a tapered cross-sectional dimension such that the cross-sectional area of the shaft distal portion lumen 207 is larger at the proximal end of the curved section than at the distal end of the curved section. In one embodiment, the cross-sectional area and the cross-sectional shape of the shaft distal portion exit port 205 is incrementally larger than the outer diameter of the needle proximal portion. In one embodiment, the curvature of the curved section of the shaft distal portion lumen 207 matches the desired exit trajectory of the needle proximal portion.



FIG. 9 is an exploded, isometric view of one embodiment of a handle of a system for treating benign prostatic hyperplasia. The handle 100 includes a right handle case 103, a left handle case 104, and a cartridge bay 101 formed in the left handle case 104. The handle 100 is designed to transmit the energy stored in several springs (not pictured) within the handle 100 to a cartridge to enable the treatment of a patient. The energy is transmitted via the interaction of various mechanisms within the handle 100. A removable scope seal 105 covers the cartridge bay 101 and couples to the scope tube 102.


The mechanisms in the handle 100 include a handle trigger assembly 110, which is operatively connected to a handle trigger spring (not pictured) such that the handle trigger spring provides force sufficient to return the handle trigger assembly 110 to its initial position after the handle trigger assembly 110 has been squeezed and released by a user. A ratchet 114, which is connected to a ratchet spring (not pictured), affects the motion of the handle trigger assembly 110 such that the handle trigger assembly 110 does not return to its initial position prior to being moved (e.g. squeezed) to a predetermined position by a user. A safety 112 is connected to the handle trigger assembly 110 to ensure that the handle trigger assembly 110 is not operated accidentally. The handle trigger assembly 110 is connected to a drive gear 113, which is connected to a cam wheel 120.


The cam wheel 120 rotates about a central axis and, via structures and features on the cam wheel, triggers certain motions within the handle 100 as the cam wheel 120 rotates. There are multiple sleds operatively connected to the cam wheel 120, and the sleds move in a linear direction along a lateral axis of the handle 100. There are multiple springs that impart force to the multiple sleds to provide mechanical energy sufficient to deliver an implant. A cartridge includes multiple tab assemblies that mate with the sleds via slots in the sled such that the energy imparted by the operation of the mechanisms in the handle (such as the springs) is transmitted to the mechanisms in the cartridge.


A wheel actuator 125 is operatively connected to the cam wheel 120 and an implant sled 160, which is connected to an implant spring that provides energy related to the delivery of the implant. A needle sled 140 is operatively connected to the cam wheel 120 and an axle 145, and a needle sled spring provides energy related to the delivery of the implant. A suture sled 150 is operatively connected to the cam wheel 120, and a suture sled spring provides energy related to the delivery of the implant.


The handle 100 includes various other parts, such as a cover plate 130, a scope lock 170, a sheath lock 180, and various screws and/or fasteners to assemble the handle. The cover plate 130 provides the interior base for the cartridge bay 101. The scope tube 102, the scope lock 170, the scope seal 105, and the sheath lock 180 provide functionality for attaching an endoscope and other ancillary equipment (such as a surgical sheath) to facilitate the procedure.



FIG. 10 is an exploded, isometric view of one embodiment of a cartridge of a system for treating benign prostatic hyperplasia. In this embodiment, the cartridge 200 includes a cartridge cover 299 coupled to a cartridge base 298. These two parts couple with a shaft support 297 to form the cartridge body. The cartridge knob 203 couples to the cartridge cover 299.


The shaft support 297 is attached to the shaft assembly 202, which includes the shaft distal portion 204. An atraumatic tape 296 is present on a surface of the shaft distal portion 204 and helps reduce tissue trauma that could result from the tissue interacting with the various openings and joints on the shaft distal portion 204 (such as those described in FIGS. 5A and 5B). The proximal anchor component 84 is contained within the shaft distal portion 204 in a configuration that is separate and disconnected from the distal anchor component 70 and the suture portion (as described herein with respect to FIG. 3).


When the proximal anchor component 84 is connected to the distal anchor component 70 and the suture portion 78 as part of the implant deployment process, it is done via the action of the pusher assembly, which includes a pusher 242 connected with a pusher block 244. A cutter assembly, which cuts the suture 222 to create the suture portion 78 during the implant deployment process, includes a cutter 232 and a cutter block 234. The movement of the cutter assembly and the pusher assembly is coordinated by the interactions of the cutter pawl 236, the implant actuator 246, and the implant spring 248, as is described in more detail herein.


A suture assembly includes the suture 222, a suture support tube 224, a suture safety 226, and a suture proximal portion 228. The distal anchor component 70 is attached to a distal end portion of the suture 222 as described herein with respect to FIG. 3. The distal portion of the suture assembly and the distal anchor component 70 are contained within the needle assembly distal portion 212, which in turn is contained within the shaft assembly until the needle assembly distal portion 212 is moved into tissue during the implant deployment process. The movement of the needle assembly proximal portion 216 and the suture assembly proximal portion 228 is coordinated via the interaction of these features with mechanisms in the handle 100, as is described in more detail herein.


Referring again to the implant deployment process and to FIGS. 3, 4A, 4B, and 10, the anchor assembly (or implant) is deployed via a sequence of steps. The needle distal portion 212 extends from a shaft distal portion 204 to a fully extended position such that at least part of the needle distal portion 212 penetrates a tissue surface in a patient, such as the outer capsule of the prostate gland. The distal anchor component 70 and a distal portion of the suture 222 are contained within the needle distal portion 212 and move with the needle distal portion 212 to penetrate tissue.


Next, while the distal anchor component 70 and a distal portion of the suture 222 are held in place, the needle assembly 210 moves proximally such that the needle distal portion 212 moves to a partially retracted position. That is, the needle distal portion 212 moves proximally with respect to its fully extended position but is not yet completely retracted within the shaft assembly 202. The suture support tube 224 helps maintain the position of the distal anchor component 70 and a distal portion of the suture 222 while the needle assembly 210 moves proximally. Thus, the distal anchor component 70 and a distal portion of the suture 222 remain near the tissue surface and are no longer within the needle distal portion 212.


In a next step, the needle assembly 210 moves further proximally to be retracted within the shaft assembly 202 while the suture assembly also moves proximally. The tail portion 74 of the distal anchor component 70 is pulled snug against the tissue surface, which causes the distal anchor component 70 to pivot about the mid-section 80 such that the distal anchor component 70 is now transverse to a distal portion of the suture 222.


In a next step, the pusher assembly moves distally to push the proximal anchor component onto a distal portion of the suture 222 and this movement defines the suture portion 78 that becomes a component of the final anchor assembly implanted in the patient. And the cutter assembly moves proximally to pull a cutting edge through the suture. At this point, the anchor assembly is now completely detached from the cartridge and handle system.


The handle and cartridge system enables the multiple steps of deploying an anchor assembly through multiple squeezes of the handle trigger assembly by the user. That is, the relative motions of all the mechanisms in the handle and cartridge and the timing of those motions occurs via multiple squeezes of the handle trigger assembly. Referring now to FIG. 9, the handle trigger assembly 110 interacts with the cam wheel 120 via the drive gear 113 and the ratchet 114. The cam wheel 120 is the principal mechanism for the way in which the handle trigger assembly 110 drives the motion and timing of the various mechanisms in the handle and cartridge system.



FIGS. 11A and 11B are side views of a cam wheel within one embodiment of a handle of a system for treating benign prostatic hyperplasia. The cam wheel 120 is mounted on an axle molded into the right handle case. The left side of the cam wheel 120, shown in FIG. 11A, includes raised features 121a, 121b, and 121c. The raised features 121a, 121b, and 121c interact with other mechanisms in the handle (such as the various sleds) to facilitate the motion of the various assemblies in the cartridge (such as the needle assembly, suture assembly, pusher assembly, and cutter assembly). The right side of the cam wheel 120, shown in FIG. 11B, includes cam wheel gear teeth 123, which interact with the drive gear 113 (pictured in FIG. 9) to transmit the generally linear motion from squeezing the handle trigger assembly 110 to the circular motion of the cam wheel 120.



FIG. 12A is a view of the left side of a cam wheel and certain other mechanical features within one embodiment of a handle and cartridge of a system for treating benign prostatic hyperplasia. FIG. 12B is the same view as FIG. 12A with the cam wheel and other mechanical features in a different configuration than shown in FIG. 12A. In this embodiment the raised feature 121c on the cam wheel 120 is designed to interact with the wheel actuator 125 to release the pusher block 244 and then allow the wheel actuator 125 to be reset. When the cam wheel 120 rotates as a consequence of the user squeezing the handle trigger assembly, the raised feature 121c pushes against a wheel actuator head portion 126 causing the wheel actuator 125 to pivot about the wheel actuator axis 129. As the wheel actuator 125 pivots, the wheel actuator tail portion 127 interacts with the implant actuator 246 causing the implant actuator 246 to pivot. When the implant actuator 246 pivots, the pusher block 244 is released from a held position and allowed to move distally and push the proximal anchor component onto the suture as described elsewhere herein. Further rotation of the cam wheel 120 moves the raised feature 121c entirely past the wheel actuator head portion 126 such that the wheel actuator 125 can pivot back into its original position. The force necessary for returning the wheel actuator 125 to its original position is supplied by the wheel actuator flexure 128, which is flexed against the handle case during the pivot of the wheel actuator 125. Flexing the wheel actuator flexure 128 stores spring energy that is released to move the wheel actuator 125 back to its original position when the wheel actuator head portion 126 is clear of the raised feature 121c. The wheel actuator 125 is thus reset to be able to interact with the implant actuator 246 of the next cartridge that is mechanically engaged with the handle.


The implant actuator 246 and the pusher block 244 (as well as the proximal anchor component and the suture) are present in the cartridge while the cam wheel 120 and the wheel actuator 125 are present in the handle. FIGS. 12A and 12B illustrate the operation of these features when the cartridge and handle are mechanically engaged as described elsewhere herein. For clarity, other features are not pictured in FIGS. 12A and 12B but certain of those features are illustrated in FIGS. 13A and 13B.



FIG. 13A is a side view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia. FIG. 13B is the same view as FIG. 13A with the mechanical features in a different configuration than shown in FIG. 13A. The pusher block 244 is coupled to the cutter block 234 by the implant spring 248. Both the pusher block 244 and the cutter block 234 are constrained to move linearly along the long axis of the cartridge by the cartridge base 298 and shaft support 297 (each pictured in FIG. 10) that define the cartridge body. The implant spring 248 is an extension spring stretched between the pusher block 244 and the cutter block 234 and exerting a force that tends to draw the pusher block 244 and the cutter block 234 toward each other. The implant actuator 246 prevents the pusher block 244 from moving under the force of the implant spring 248 when the implant actuator 246 is in the configuration depicted in FIG. 13A (and FIG. 12A). The cutter pawl distal end 237 prevents the cutter block 234 from moving under the force of the implant spring 248 when the cutter pawl 236 is in the configuration depicted in FIG. 13A. When the implant actuator 246 is made to pivot as described herein with respect to FIGS. 12A and 12B, the pusher block 244 moves distally (i.e., the pusher assembly moves in the direction of arrow “P”) to push the proximal anchor component onto the suture as described elsewhere herein. During this motion, which is driven by the force of the implant spring 248, the pusher block 244 interacts with the cutter pawl proximal end 238 and causes the cutter pawl 236 to pivot as depicted in FIG. 13B. The sloped front surface of the pusher block 244 and the curved surface of the cutter pawl proximal end 238 interact to create this pivoting motion. When the cutter pawl 236 pivots, the cutter pawl distal end 237 disengages from the cutter block 234 and allows the cutter block 234 to move proximally under the force of implant spring 248. The proximal motion of the cutter block 234 causes the suture to be cut to form the suture portion of the anchor assembly. That is, the cutter assembly moves in the direction of arrow “C” to complete the anchor assembly and detach it from the cartridge and handle system.


As described elsewhere herein, in some embodiments multiple cartridges can be used in serial fashion with a single handle. The steps and mechanisms illustrated and explained with respect to FIGS. 12A, 12B, 13A, and 13B disclose how the pushing and cutting steps of creating the anchor assembly can be repeatedly executed for multiple engagements of a series of cartridges with a single handle. One notable feature is that the implant spring is in an extended state as its initial condition. It is important, then, for the cartridge to have features that prevent the unintended release of the energy in the implant spring during handling of the cartridge.



FIG. 14 is a side view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia. FIG. 14 illustrates the mechanisms depicted in FIG. 13A (in the configuration of FIG. 13A) with the addition of the cartridge knob 203 to show the operational relationship among these features. FIG. 14 illustrates the cartridge knob 203 in the storage position. In the storage position, the grip section 292 is transverse to the long axis of the cartridge as compared to the engaged position shown in FIG. 1 in which the grip section 292 is aligned with the long axis of the cartridge. When in the storage position, the cartridge knob 203 functions as a safety interlock that prevents movement by the pusher block 244. In the storage position depicted in FIG. 14, a pusher safety tab 293 on the cartridge knob 203 engages with the distal end of the implant actuator 246 and prevents the implant actuator 246 from pivoting to release the pusher block 244 (as illustrated and explained with respect to FIGS. 12A and 12B). The pusher safety tab 293 allows the cartridge to be safely handled and stored while the implant spring is in its extended configuration.



FIG. 15A is an exploded top view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia and 15B is an exploded perspective view of the same features. FIGS. 15A and 15B illustrate another safety interlock in which a cutter safety tab 286 is present on the cutter pawl 236. The cutter safety tab 286 engages with the cartridge knob 203 when the cartridge knob 203 is in the storage position and prevents the cutter pawl 236 from pivoting to release the cutter block (as illustrated and explained with respect to FIGS. 13A and 13B). The cutter safety tab 286 allows the cartridge to be safely handled and stored while the implant spring is in its extended configuration. FIGS. 15A and 15B are illustrated in an exploded view to make the relevant features clear. However, in operation the cutter pawl 236 is closely engaged with the cartridge knob 203 to create the mechanical interactions described herein.


The pusher safety tab 293 and the cutter safety tab 286 solve the problem of accidental firing of the pusher assembly and/or cutter assembly in the cartridge by correlating safety interlocks with the storage position of the cartridge knob 203.



FIGS. 16A, 16B, 17, 18A, and 18B illustrate an embodiment of another safety interlock mechanism in the handle and cartridge system. FIG. 16A is a perspective view of a portion of a handle 100 and FIG. 16B is a side view of the handle 100. The handle 100 includes a cartridge bay 101, which is shown as empty because the cartridge has been removed. In this embodiment, the handle trigger assembly 110 includes cartridge lock tab 111 that protrudes into the cartridge bay 101 when the handle trigger assembly 110 pivots away from the handle grip 115. The presence of the cartridge lock tab 111 in the cartridge bay 101 prevents a cartridge from being engaged with the handle 100 because a cartridge cannot physically fit in the cartridge bay 101 with the cartridge lock tab 111 in the cartridge bay 101. This mechanism prevents a cartridge from being inserted into the handle except under the proper condition—when the handle trigger assembly 110 is in its initial position closest to the handle grip 115. This initial position corresponds with the mechanisms in the handle all being reset to their initial positions.



FIG. 17 is a side view of a portion of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia. In FIG. 17, the cartridge cover has been removed, revealing the cartridge base 298. The cartridge knob 203 is also shown. A cartridge lock surface 291 is present on the shaft support 297 and extends below the cartridge base 298 in this side view of a portion of a cartridge.



FIGS. 18A and 18B are a perspective view and a side view, respectively, of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia. FIGS. 18A and 18B illustrate the interaction between the cartridge lock tab 111 present on the handle trigger assembly 110 and the cartridge lock surface 291 present on the shaft support 297. When the handle trigger assembly 110 is in a position pivoted away from the handle grip, the cartridge lock tab 111 prevents the cartridge from being removed from the cartridge bay by physically impeding the removal of the cartridge. While the cartridge lock surface 291 is present on the shaft support 297 in this embodiment, a similar lock surface could be present on other parts of the cartridge, such as the cartridge base 298, and function in a substantially similar manner.


The cartridge lock tab 111 present on the handle trigger assembly 110 provides a method of preventing insertion of a cartridge until the handle is in the reset, initial condition, and prevents removal of a cartridge (via interaction with the cartridge lock surface 291) while the handle and cartridge system is in use. There are alternative embodiments for preventing removal and/or insertion of a cartridge. For example, a cartridge may contain a lock receiving feature and the handle may contain an additional wheel with a series of locking features. As the handle trigger is pulled, the additional wheel rotates such that a locking feature engages the lock receiver. If a complete cycle for implantation requires multiple trigger squeezes, then the additional wheel includes sufficient locking features to keep the cartridge locked in during the entire cycle. At the end of the cycle, a portion of the additional wheel containing no locking feature is aligned with the lock receiver. In this way, the cartridge would be unlocked and removable from the handle. As another example, a locking slide could be engaged by a user to lock the cartridge in the handle. When the trigger is squeezed, the slide would be mechanically engaged to prevent the slide from moving until the cycle was completed.



FIGS. 19A and 19B are side views of a portion of a cartridge of one embodiment of a system for treating benign prostatic hyperplasia. The cartridge knob 203 is engaged with the cartridge cover 299, which includes a cartridge indicator window 290. In FIG. 19A, the cutter block 234 is visible through the cartridge indicator window 290, which indicates that the cutter block 234 is still in its initial position and has not moved proximally to cut the suture in the final step of the formation of the anchor assembly. FIG. 19A shows that the cutter block 234 fills the cartridge indicator window 290. In FIG. 19B, only a small portion of the cutter block 234 is visible through the cartridge indicator window 290. That is, the cutter block 234 no longer fills the cartridge indicator window 290. This indicates that the cutter block 234 has moved proximally and cut the suture for the final step of the formation of the anchor assembly.



FIG. 19C is a perspective view of a cartridge cover of one embodiment of a system for treating benign prostatic hyperplasia. FIG. 19C illustrates that the cartridge indicator window 290 is cut through the distal surface of the cartridge cover 299. The cartridge indicator window 290 is able to perform an additional function of providing access to the cutter block 234 such that a user can use a small tool to move the cutter block distally to cut the suture if the cutter block 234 stalls and does not completely cut the suture. The presence of an opening to the cartridge indicator window 290 through the distal surface of the cartridge cover 299 allows for easy access to the cutter block 234 with a tool, even when the user is not looking directly at the cartridge indicator window 290.



FIG. 20A is an exploded perspective view of certain mechanical features within one embodiment of a cartridge of a system for treating benign prostatic hyperplasia and FIG. 20B is a side view of those mechanical features in their engaged configuration. As described herein with respect to FIGS. 13A and 13B, in normal operation the cutter pawl 236 pivots and disengages from the cutter block allowing the cutter block to move proximally under the force of the implant spring. The proximal motion of the cutter block causes the suture to be cut to form the suture portion of the anchor assembly. However, in some circumstances it may be desirable for a user to interrupt the deployment sequence after deployment of the distal anchor component but prior to the deployment of the proximal anchor component and cutting of the suture. In such a circumstance, the handle and cartridge system can then be removed from the patient without completely assembling and deploying the implant.



FIGS. 20A and 20B illustrate that the cutter pawl 236 includes a cutter manual tab 284 that is accessible to a user via a cutter access window 288 present on the cartridge knob 203. The cutter manual tab 284 is configured as an off-center ramp such that pushing on the cutter manual tab 284 through the cutter access window 288 creates rotation (or pivoting) of the cutter pawl 236 perpendicular to the push direction. A user can push the cutter manual tab 284 with a small tool inserted through the cutter access window 288. Indentations in the cartridge knob 203 near the cutter access window 288 guide the tool towards the cutter access window 288. As described herein, this pivoting of the cutter pawl 236 disengages the cutter pawl from the cutter block and allows the cutter block to move proximally under the force of the implant spring to cut the suture.


The disclosed apparatus can be implemented in various treatment devices employed for various medical purposes including, but not limited to, retracting, lifting, compressing, approximating, supporting, remodeling, repositioning, ablating, or otherwise altering tissues, organs, anatomical structures, grafts, or other material found within the body of a human or animal subject. In certain embodiments, treatment devices are intended to displace, compress, retract, or destroy tissue of the prostate to facilitate treatment of diseases or disorders such as BPH.


Other treatment devices may benefit from the use of the embodiments disclosed herein. Treatment devices equipped with various tools which manipulate, ablate, or otherwise alter tissue, where those tools are moved, deployed, or driven by mechanical energy, can benefit from the use of the safety interlocks and mechanisms, as well as the use of the deployment indicators, disclosed herein. Such tools can include, but are not limited to, needles, cutting blades, vacuums, grasping arm assemblies, expandable cutting members, blunt dissectors, noose or ligature clips, articulating heads with an integral or retractable blade, helical blades, electrodes for delivery of radiofrequency energy, cutting wires or rings, electrocauterizing probes, or staple or suture delivery heads.


In some embodiments, the system includes a cartridge carrying at least one implant and a handle configured to receive the cartridge. The handle includes an actuator and at least one spring mechanism loaded with mechanical energy. The handle also includes a member that mates with the cartridge to transfer mechanical energy from the spring mechanism to the cartridge for deploying the implant. The handle and cartridge system includes a first firing sled that has slots aligning with pusher tabs on a needle assembly. The slots of the first firing sled and the pusher tabs of the needle assembly are complementary mechanisms that allow for the transfer of energy from the spring mechanism via the first firing sled to fire a needle in the cartridge. The handle and cartridge system can also include a second firing sled with slots aligning with pusher tabs on a suture tube or connector tube. The slots of the second firing sled and the pusher tabs of the suture tube are complementary mechanisms that allow for the transfer of energy from the spring mechanism via the second firing sled to advance the suture tube simultaneously with the needle tube.


While particular elements, embodiments and applications of the present invention have been shown and described, it will be understood that the invention is not limited thereto since modifications can be made by those skilled in the art without departing from the scope of the present disclosure, particularly in light of the foregoing teachings.












Table of Reference Numerals
















1
system


70
distal anchor component


72
head portion


74
tail portion


78
suture portion


80
mid-section


82
connector section


84
proximal anchor component


95
back end


96
prong


98
tab


100
handle


101
cartridge bay


102
scope tube


103
right handle case


104
left handle case


105
scope seal


110
handle trigger assembly


111
cartridge lock tab


112
safety


113
drive gear


114
ratchet


115
handle grip


120
cam wheel


125
wheel actuator


126
wheel actuator head portion


127
wheel actuator tail portion


128
wheel actuator flexure


129
wheel actuator axis


130
cover plate


140
needle sled


145
axle


150
suture sled


160
implant sled


170
scope lock


180
sheath lock


200
cartridge


201
cartridge body


202
shaft assembly


203
cartridge knob


204
shaft distal portion


205
shaft distal portion exit port


206
shaft distal portion cutout


207
shaft distal portion lumen


208
shaft distal portion interior exit wall


209
shaft distal portion upper cutout


210
needle assembly


212
needle distal portion


214
needle shaft


216
needle proximal portion


220
suture assembly


222
suture


224
suture support tube


226
suture safety


228
suture proximal portion


230
cutter assembly


232
cutter


234
cutter block


236
cutter pawl


237
cutter pawl distal end


238
cutter pawl proximal end


240
pusher assembly


242
pusher


244
pusher block


246
implant actuator


248
implant spring


284
cutter manual tab


286
cutter safety tab


288
cutter access window


290
cartridge indicator window


291
cartridge lock surface


292
grip section


293
pusher safety tab


296
atraumatic tape


297
shaft support


298
cartridge base


299
cartridge cover








Claims
  • 1. A system that includes a handle and a cartridge, where the handle is configured to accept a series of such cartridges and impart mechanical energy to the cartridge to deliver an implant, comprising: a cam wheel within the handle and coupled to a trigger assembly included in the handle;a wheel actuator coupled to the cam wheel such that a feature on the cam wheel is configured to cause the wheel actuator to pivot in a first direction when the feature contacts the wheel actuator; andthe wheel actuator having a flexure that is engaged when the wheel actuator pivots in the first direction and causes the wheel actuator to pivot in a second direction opposite the first direction when the feature no longer contacts the wheel actuator.
  • 2. The system of claim 1, further comprising a slidable pusher block and an implant actuator each within the cartridge.
  • 3. The system of claim 2, wherein the implant actuator is engaged with the pusher block to prevent the pusher block from sliding.
  • 4. The system of claim 3, wherein the wheel actuator disengages the implant actuator from the pusher block when the wheel actuator pivots in the first direction.
  • 5. The system of claim 1, further comprising a trigger assembly included in the handle and a lock tab on the trigger assembly configured to enter a cartridge bay of the handle when the trigger is in a working position such that a cartridge cannot be secured within the cartridge bay when the lock tab is at least partially within the cartridge bay.
  • 6. The system of claim 5, further comprising a lock surface on the cartridge configured to be engaged by the lock tab such that the cartridge cannot be removed from the cartridge bay when the trigger is in the working position.
  • 7. The system of claim 6, wherein the cartridge can be removed from the cartridge bay when the trigger is in an initial position.
  • 8. The system of claim 7, wherein the implant comprises a distal anchor component, a suture portion, and a proximal anchor component.
  • 9. The system of claim 8, wherein the pusher block is configured to push the proximal anchor component onto the suture portion.
  • 10. The system of claim 4, wherein the implant comprises a distal anchor component, a suture portion, and a proximal anchor component.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional patent application No. 63/060,442, entitled “HANDLE AND CARTRIDGE SYSTEM FOR MEDICAL INTERVENTIONS” and filed on Aug. 3, 2020, which is herein incorporated by reference in its entirety.

US Referenced Citations (588)
Number Name Date Kind
659422 Shidler Oct 1900 A
780392 Wanamaker et al. Jan 1905 A
789467 West May 1905 A
2360164 Frank Oct 1944 A
2485531 William et al. Oct 1949 A
2579192 Alexander Dec 1951 A
2646298 Leary Jul 1953 A
2697624 Thomas et al. Dec 1954 A
2734299 Masson Feb 1956 A
2825592 Mckenzie Mar 1958 A
3326586 Frost et al. Jun 1967 A
3470834 Bone Oct 1969 A
3521918 Hammond Jul 1970 A
3541591 Hoegerman Nov 1970 A
3664345 Dabbs et al. May 1972 A
3713680 Pagano Jan 1973 A
3716058 Tanner Feb 1973 A
3756638 Stockberger Sep 1973 A
3873140 Bloch Mar 1975 A
3875648 Bone Apr 1975 A
3886933 Mori et al. Jun 1975 A
3931667 Merser et al. Jan 1976 A
3976079 Samuels et al. Aug 1976 A
4006747 Kronenthal et al. Feb 1977 A
4137920 Bonnet Feb 1979 A
4164225 Johnson et al. Aug 1979 A
4210148 Stivala Jul 1980 A
4235238 Ogiu et al. Nov 1980 A
4291698 Fuchs et al. Sep 1981 A
4409974 Freedland Oct 1983 A
4419094 Patel Dec 1983 A
4493323 Albright et al. Jan 1985 A
4513746 Aranyi et al. Apr 1985 A
4621640 Mulhollan et al. Nov 1986 A
4655771 Wallsten Apr 1987 A
4657461 Smith Apr 1987 A
4669473 Richards et al. Jun 1987 A
4705040 Mueller et al. Nov 1987 A
4714281 Peck Dec 1987 A
4738255 Goble et al. Apr 1988 A
4741330 Hayhurst May 1988 A
4744364 Kensey May 1988 A
4750492 Jacobs Jun 1988 A
4762128 Rosenbluth Aug 1988 A
4823794 Pierce Apr 1989 A
4863439 Sanderson Sep 1989 A
4899743 Nicholson et al. Feb 1990 A
4926860 Stice et al. May 1990 A
4946468 Li Aug 1990 A
4955913 Robinson Sep 1990 A
4968315 Gatturna Nov 1990 A
5002550 Li Mar 1991 A
5019032 Robertson May 1991 A
5041129 Hayhurst et al. Aug 1991 A
5046513 Gatturna et al. Sep 1991 A
5053046 Janese Oct 1991 A
5078731 Hayhurst Jan 1992 A
5080660 Buelna Jan 1992 A
5098374 Othel-Jacobsen et al. Mar 1992 A
5100421 Christoudias Mar 1992 A
5123914 Cope Jun 1992 A
5127393 McFarlin et al. Jul 1992 A
5129912 Noda et al. Jul 1992 A
5133713 Huang et al. Jul 1992 A
5159925 Neuwirth et al. Nov 1992 A
5160339 Chen et al. Nov 1992 A
5192303 Gatturna et al. Mar 1993 A
5203787 Noblitt et al. Apr 1993 A
5207672 Roth et al. May 1993 A
5217470 Weston Jun 1993 A
5217486 Rice et al. Jun 1993 A
5234454 Bangs Aug 1993 A
5236445 Hayhurst et al. Aug 1993 A
5237984 Williams et al. Aug 1993 A
5258015 Li et al. Nov 1993 A
5267960 Hayman et al. Dec 1993 A
5269802 Garber Dec 1993 A
5269809 Hayhurst et al. Dec 1993 A
5300099 Rudie Apr 1994 A
5322501 Mahmud-Durrani Jun 1994 A
5330488 Goldrath Jul 1994 A
5334200 Johnson Aug 1994 A
5336240 Metzler et al. Aug 1994 A
5354271 Voda Oct 1994 A
5358511 Gatturna et al. Oct 1994 A
5364408 Gordon Nov 1994 A
5366490 Edwards et al. Nov 1994 A
5368599 Hirsch et al. Nov 1994 A
5370646 Reese et al. Dec 1994 A
5380334 Torrie et al. Jan 1995 A
5391182 Chin Feb 1995 A
5403348 Bonutti Apr 1995 A
5405352 Weston Apr 1995 A
5411520 Nash et al. May 1995 A
5417691 Hayhurst May 1995 A
5435805 Edwards et al. Jul 1995 A
5470337 Moss Nov 1995 A
5472446 Torre Dec 1995 A
5478003 Green et al. Dec 1995 A
5480406 Nolan et al. Jan 1996 A
5499994 Tihon et al. Mar 1996 A
5501690 Measamer et al. Mar 1996 A
5507754 Green et al. Apr 1996 A
5522846 Bonutti Jun 1996 A
5531763 Mastri et al. Jul 1996 A
5536240 Edwards et al. Jul 1996 A
5540655 Edwards et al. Jul 1996 A
5540704 Gordon et al. Jul 1996 A
5545171 Sharkey et al. Aug 1996 A
5545178 Kensey et al. Aug 1996 A
5549631 Bonutti Aug 1996 A
5550172 Regula et al. Aug 1996 A
5554162 DeLange Sep 1996 A
5554171 Gatturna et al. Sep 1996 A
5562689 Green et al. Oct 1996 A
5569305 Bonutti Oct 1996 A
5571104 Li Nov 1996 A
5573540 Yoon Nov 1996 A
5578044 Gordon et al. Nov 1996 A
5591177 Lehrer Jan 1997 A
5593421 Bauer Jan 1997 A
5611515 Benderev et al. Mar 1997 A
5626614 Hart May 1997 A
5630824 Hart May 1997 A
5647836 Blake et al. Jul 1997 A
5665109 Yoon Sep 1997 A
5667486 Mikulich et al. Sep 1997 A
5667488 Lundquist et al. Sep 1997 A
5669917 Sauer et al. Sep 1997 A
5690649 Li Nov 1997 A
5690677 Schmieding et al. Nov 1997 A
5697950 Fucci et al. Dec 1997 A
5707394 Miller et al. Jan 1998 A
5716368 Torre et al. Feb 1998 A
5718717 Bonutti Feb 1998 A
5725556 Moser et al. Mar 1998 A
5725557 Gatturna et al. Mar 1998 A
5733306 Bonutti Mar 1998 A
5741276 Poloyko et al. Apr 1998 A
5746753 Sullivan et al. May 1998 A
5749846 Edwards et al. May 1998 A
5749889 Bacich et al. May 1998 A
5752963 Allard et al. May 1998 A
5782862 Bonutti Jul 1998 A
5782864 Lizardi Jul 1998 A
5791022 Bohman Aug 1998 A
5800445 Ratcliff et al. Sep 1998 A
5807403 Beyar et al. Sep 1998 A
5810848 Hayhurst Sep 1998 A
5810853 Yoon Sep 1998 A
5814072 Bonutti Sep 1998 A
5830179 Mikus et al. Nov 1998 A
5830221 Stein et al. Nov 1998 A
5845645 Bonutti Dec 1998 A
5846254 Schulze et al. Dec 1998 A
5861002 Desai Jan 1999 A
5868762 Cragg et al. Feb 1999 A
5873891 Sohn Feb 1999 A
5879357 Heaton et al. Mar 1999 A
5897574 Bonutti Apr 1999 A
5899911 Carter May 1999 A
5899921 Caspari et al. May 1999 A
5904679 Clayman May 1999 A
5904696 Rosenman May 1999 A
5908428 Scirica et al. Jun 1999 A
5908447 Schroeppel et al. Jun 1999 A
5919198 Graves et al. Jul 1999 A
5919202 Yoon Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5921986 Bonutti Jul 1999 A
5928252 Steadman et al. Jul 1999 A
5931844 Thompson et al. Aug 1999 A
5944739 Zlock et al. Aug 1999 A
5948001 Larsen Sep 1999 A
5948002 Bonutti Sep 1999 A
5954057 Li Sep 1999 A
5954731 Yoon Sep 1999 A
5954747 Clark Sep 1999 A
5964732 Willard Oct 1999 A
5971447 Steck Oct 1999 A
5971967 Willard Oct 1999 A
6010514 Burney et al. Jan 2000 A
6011525 Piole Jan 2000 A
6015428 Pagedas Jan 2000 A
6030393 Corlew Feb 2000 A
6033413 Mikus et al. Mar 2000 A
6033430 Bonutti Mar 2000 A
6036701 Rosenman Mar 2000 A
6048351 Gordon et al. Apr 2000 A
6053908 Crainich et al. Apr 2000 A
6056722 Jayaraman May 2000 A
6056772 Bonutti May 2000 A
6066160 Colvin et al. May 2000 A
6068648 Cole et al. May 2000 A
6080167 Lyell Jun 2000 A
6086608 Ek et al. Jul 2000 A
6110183 Cope Aug 2000 A
6117133 Zappala Sep 2000 A
6117160 Bonutti Sep 2000 A
6117161 Li et al. Sep 2000 A
6120539 Eldridge et al. Sep 2000 A
6132438 Fleischman et al. Oct 2000 A
6139555 Hart et al. Oct 2000 A
RE36974 Bonutti Nov 2000 E
6143006 Chan Nov 2000 A
6152935 Kammerer et al. Nov 2000 A
6156013 Mahurkar Dec 2000 A
6156044 Kammerer et al. Dec 2000 A
6159207 Yoon Dec 2000 A
6159234 Bonutti et al. Dec 2000 A
6200329 Fung et al. Mar 2001 B1
6206895 Levinson Mar 2001 B1
6206907 Marino et al. Mar 2001 B1
6228096 Marchand May 2001 B1
6258124 Darois et al. Jul 2001 B1
6261302 Voegele et al. Jul 2001 B1
6270530 Eldridge et al. Aug 2001 B1
6280460 Bolduc et al. Aug 2001 B1
6287317 Makower et al. Sep 2001 B1
6290711 Caspari et al. Sep 2001 B1
6306158 Bartlett Oct 2001 B1
6312448 Bonutti Nov 2001 B1
6319263 Levinson Nov 2001 B1
6322112 Duncan Nov 2001 B1
6332889 Sancoff et al. Dec 2001 B1
6382214 Raz et al. May 2002 B1
6398795 McAlister et al. Jun 2002 B1
6423079 Blake, III Jul 2002 B1
6425900 Knodel et al. Jul 2002 B1
6425919 Lambrecht Jul 2002 B1
6428562 Bonutti Aug 2002 B2
6436107 Wang et al. Aug 2002 B1
6461355 Svejkovsky et al. Oct 2002 B2
6482235 Lambrecht et al. Nov 2002 B1
6488691 Carroll et al. Dec 2002 B1
6491707 Makower et al. Dec 2002 B2
6494888 Laufer et al. Dec 2002 B1
6500184 Chan et al. Dec 2002 B1
6500195 Bonutti Dec 2002 B2
6506190 Walshe Jan 2003 B1
6506196 Laufer Jan 2003 B1
6517569 Mikus et al. Feb 2003 B2
6527702 Whalen et al. Mar 2003 B2
6527794 McDevitt et al. Mar 2003 B1
6530932 Swayze et al. Mar 2003 B1
6533796 Sauer et al. Mar 2003 B1
6544230 Flaherty et al. Apr 2003 B1
6547725 Paolitto et al. Apr 2003 B1
6551328 Kortenbach Apr 2003 B2
6551333 Kuhns et al. Apr 2003 B2
6565578 Peifer et al. May 2003 B1
6569187 Bonutti et al. May 2003 B1
6572626 Knodel et al. Jun 2003 B1
6572635 Bonutti Jun 2003 B1
6572653 Simonson Jun 2003 B1
6582453 Tran et al. Jun 2003 B1
6592609 Bonutti Jul 2003 B1
6596013 Yang et al. Jul 2003 B2
6599311 Biggs et al. Jul 2003 B1
6626913 McKinnon et al. Sep 2003 B1
6626916 Yeung et al. Sep 2003 B1
6626919 Swanstrom Sep 2003 B1
6629534 Goar et al. Oct 2003 B1
6641524 Kovac Nov 2003 B2
6641592 Sauer et al. Nov 2003 B1
6656182 Hayhurst Dec 2003 B1
6660008 Foerster et al. Dec 2003 B1
6660023 McDevitt et al. Dec 2003 B2
6663589 Halevy Dec 2003 B1
6663633 Pierson Dec 2003 B1
6663639 Laufer et al. Dec 2003 B1
6699263 Cope Mar 2004 B2
6702846 Mikus et al. Mar 2004 B2
6706047 Trout et al. Mar 2004 B2
6709493 DeGuiseppi et al. Mar 2004 B2
6715804 Beers Apr 2004 B2
6719709 Whalen et al. Apr 2004 B2
6730112 Levinson May 2004 B2
6736823 Darois et al. May 2004 B2
6736854 Vadurro et al. May 2004 B2
6740098 Abrams et al. May 2004 B2
6767037 Wenstrom Jul 2004 B2
6770076 Foerster Aug 2004 B2
6773438 Knodel et al. Aug 2004 B1
6773441 Laufer et al. Aug 2004 B1
6790213 Cherok et al. Sep 2004 B2
6802846 Hauschild et al. Oct 2004 B2
6821282 Perry et al. Nov 2004 B2
6821285 Laufer et al. Nov 2004 B2
6821291 Bolea et al. Nov 2004 B2
6835200 Laufer et al. Dec 2004 B2
6905475 Hauschild et al. Jun 2005 B2
6908473 Skiba et al. Jun 2005 B2
6921361 Suzuki et al. Jul 2005 B2
6926732 Derus et al. Aug 2005 B2
6951565 Keane et al. Oct 2005 B2
6986775 Morales et al. Jan 2006 B2
6986784 Weiser et al. Jan 2006 B1
6991596 Whalen et al. Jan 2006 B2
6991647 Jadhav Jan 2006 B2
6997940 Bonutti Feb 2006 B2
7001327 Whalen et al. Feb 2006 B2
7008381 Janssens Mar 2006 B2
7011688 Gryska et al. Mar 2006 B2
7015253 Escandon et al. Mar 2006 B2
7041111 Chu May 2006 B2
7048698 Whalen et al. May 2006 B2
7048747 Arcia et al. May 2006 B2
7060077 Gordon et al. Jun 2006 B2
7063715 Onuki et al. Jun 2006 B2
7081126 McDevitt et al. Jul 2006 B2
7083638 Foerster Aug 2006 B2
7087073 Bonutti Aug 2006 B2
7089064 Manker et al. Aug 2006 B2
7090690 Foerster et al. Aug 2006 B2
7093601 Manker et al. Aug 2006 B2
7105004 DiCesare et al. Sep 2006 B2
7108655 Whalen et al. Sep 2006 B2
7141038 Whalen et al. Nov 2006 B2
7153314 Laufer et al. Dec 2006 B2
7179225 Shluzas et al. Feb 2007 B2
7226558 Nieman et al. Jun 2007 B2
7232448 Battles et al. Jun 2007 B2
7255675 Gertner et al. Aug 2007 B2
7288063 Petros et al. Oct 2007 B2
7303108 Shelton Dec 2007 B2
7320701 Haut et al. Jan 2008 B2
7322974 Swoyer et al. Jan 2008 B2
7326221 Sakamoto et al. Feb 2008 B2
7334822 Hines Feb 2008 B1
7340300 Christopherson et al. Mar 2008 B2
7399304 Gambale et al. Jul 2008 B2
7402166 Feigl Jul 2008 B2
7416554 Lam et al. Aug 2008 B2
7417175 Oda et al. Aug 2008 B2
7463934 Tronnes et al. Dec 2008 B2
7481771 Fonseca et al. Jan 2009 B2
7553317 William et al. Jun 2009 B2
7608108 Bhatnagar et al. Oct 2009 B2
7645286 Catanese et al. Jan 2010 B2
7658311 Boudreaux Feb 2010 B2
7674275 Martin et al. Mar 2010 B2
7695494 Foerster Apr 2010 B2
7704261 Sakamoto et al. Apr 2010 B2
7727248 Smith et al. Jun 2010 B2
7736374 Vaughan et al. Jun 2010 B2
7758594 Lamson et al. Jul 2010 B2
7766923 Catanese et al. Aug 2010 B2
7766939 Yeung et al. Aug 2010 B2
7780682 Catanese et al. Aug 2010 B2
7815655 Catanese et al. Oct 2010 B2
7887551 Bojarski et al. Feb 2011 B2
7896891 Catanese et al. Mar 2011 B2
7905889 Catanese et al. Mar 2011 B2
7909836 McLean et al. Mar 2011 B2
7914542 Lamson et al. Mar 2011 B2
7951158 Catanese et al. May 2011 B2
8007503 Catanese et al. Aug 2011 B2
8043309 Catanese et al. Oct 2011 B2
8157815 Catanese et al. Apr 2012 B2
8211118 Catanese et al. Jul 2012 B2
8216254 McLean et al. Jul 2012 B2
8333776 Cheng et al. Dec 2012 B2
8343187 Lamson et al. Jan 2013 B2
8394110 Catanese et al. Mar 2013 B2
8394113 Wei et al. Mar 2013 B2
8425535 McLean et al. Apr 2013 B2
8454655 Yeung et al. Jun 2013 B2
8491606 Tong et al. Jul 2013 B2
8529584 Catanese et al. Sep 2013 B2
8603106 Catanese et al. Dec 2013 B2
8628542 Merrick et al. Jan 2014 B2
8663243 Lamson et al. Mar 2014 B2
8668705 Johnston et al. Mar 2014 B2
8715239 Lamson et al. May 2014 B2
8715298 Catanese et al. May 2014 B2
8758366 McLean et al. Jun 2014 B2
8900252 Lamson et al. Dec 2014 B2
8936609 Catanese et al. Jan 2015 B2
8939996 Cheng et al. Jan 2015 B2
9320511 McLean et al. Apr 2016 B2
9504461 Catanese et al. Nov 2016 B2
9549739 Catanese et al. Jan 2017 B2
9931192 McLean et al. Apr 2018 B2
10105132 Lamson et al. Oct 2018 B2
10299780 Catanese et al. May 2019 B2
10349932 Catanese et al. Jul 2019 B2
10568651 Kostrzewski et al. Feb 2020 B2
10702261 Stiggelbout Jul 2020 B2
11298115 Yarra et al. Apr 2022 B2
20010041916 Bonutti Nov 2001 A1
20010044639 Levinson Nov 2001 A1
20020095064 Beyar Jul 2002 A1
20020095154 Atkinson et al. Jul 2002 A1
20020107540 Whalen et al. Aug 2002 A1
20020128684 Foerster Sep 2002 A1
20020161382 Neisz et al. Oct 2002 A1
20020183740 Edwards et al. Dec 2002 A1
20020193809 Meade et al. Dec 2002 A1
20030060819 McGovern et al. Mar 2003 A1
20030109769 Lowery et al. Jun 2003 A1
20030191497 Cope Oct 2003 A1
20030199860 Loeb et al. Oct 2003 A1
20030204195 Keane et al. Oct 2003 A1
20030229263 Connors et al. Dec 2003 A1
20030236535 Onuki et al. Dec 2003 A1
20040030217 Yeung et al. Feb 2004 A1
20040043052 Hunter et al. Mar 2004 A1
20040078046 Barzell et al. Apr 2004 A1
20040122456 Saadat et al. Jun 2004 A1
20040122474 Gellman et al. Jun 2004 A1
20040147958 Lam et al. Jul 2004 A1
20040181235 Daignault et al. Sep 2004 A1
20040193191 Starksen et al. Sep 2004 A1
20040193194 Laufer et al. Sep 2004 A1
20040194790 Laufer et al. Oct 2004 A1
20040243178 Haut et al. Dec 2004 A1
20040243179 Foerster Dec 2004 A1
20040243180 Donnelly et al. Dec 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040260345 Foerster Dec 2004 A1
20050010203 Edwards et al. Jan 2005 A1
20050055087 Starksen Mar 2005 A1
20050065550 Starksen et al. Mar 2005 A1
20050107811 Starksen et al. May 2005 A1
20050107812 Starksen et al. May 2005 A1
20050154401 Weldon et al. Jul 2005 A1
20050165272 Okada et al. Jul 2005 A1
20050177181 Kagan et al. Aug 2005 A1
20050203344 Orban et al. Sep 2005 A1
20050203550 Laufer et al. Sep 2005 A1
20050216040 Gertner et al. Sep 2005 A1
20050216078 Starksen et al. Sep 2005 A1
20050251157 Saadat et al. Nov 2005 A1
20050251206 Maahs et al. Nov 2005 A1
20050256530 Petros Nov 2005 A1
20050267405 Shah Dec 2005 A1
20050273138 To et al. Dec 2005 A1
20060025750 Starksen et al. Feb 2006 A1
20060025784 Starksen et al. Feb 2006 A1
20060025789 Laufer et al. Feb 2006 A1
20060025819 Nobis et al. Feb 2006 A1
20060026750 Ballance Feb 2006 A1
20060030884 Yeung et al. Feb 2006 A1
20060058817 Starksen et al. Mar 2006 A1
20060089646 Bonutti Apr 2006 A1
20060167477 Arcia et al. Jul 2006 A1
20060195008 Whalen et al. Aug 2006 A1
20060199996 Caraballo et al. Sep 2006 A1
20060241694 Cerundolo Oct 2006 A1
20060265042 Catanese et al. Nov 2006 A1
20060276481 Evrard et al. Dec 2006 A1
20060276871 Lamson et al. Dec 2006 A1
20060282081 Fanton et al. Dec 2006 A1
20070049929 Catanese et al. Mar 2007 A1
20070049970 Belef et al. Mar 2007 A1
20070060931 Hamilton et al. Mar 2007 A1
20070088362 Bonutti et al. Apr 2007 A1
20070112385 Conlon May 2007 A1
20070142846 Catanese et al. Jun 2007 A1
20070173888 Gertner et al. Jul 2007 A1
20070260259 Fanton et al. Nov 2007 A1
20080009888 Ewers et al. Jan 2008 A1
20080021445 Elmouelhi et al. Jan 2008 A1
20080021485 Catanese et al. Jan 2008 A1
20080033458 McLean et al. Feb 2008 A1
20080033460 Ziniti Feb 2008 A1
20080033488 Catanese et al. Feb 2008 A1
20080039833 Catanese et al. Feb 2008 A1
20080039872 Catanese et al. Feb 2008 A1
20080039874 Catanese et al. Feb 2008 A1
20080039875 Catanese et al. Feb 2008 A1
20080039893 McLean et al. Feb 2008 A1
20080039894 Catanese et al. Feb 2008 A1
20080045978 Kuhns et al. Feb 2008 A1
20080051810 To et al. Feb 2008 A1
20080058710 Wilk Mar 2008 A1
20080065120 Zannis et al. Mar 2008 A1
20080082113 Bishop et al. Apr 2008 A1
20080086172 Martin et al. Apr 2008 A1
20080091220 Chu Apr 2008 A1
20080091237 Schwartz et al. Apr 2008 A1
20080119874 Merves May 2008 A1
20080154378 Pelo Jun 2008 A1
20080161852 Kaiser et al. Jul 2008 A1
20080195145 Bonutti et al. Aug 2008 A1
20080208220 Shiono et al. Aug 2008 A1
20080228202 Cropper et al. Sep 2008 A1
20080262424 Hooft Oct 2008 A1
20080269737 Elmouelhi et al. Oct 2008 A1
20090012537 Green Jan 2009 A1
20090018553 McLean et al. Jan 2009 A1
20090060977 Lamson et al. Mar 2009 A1
20090112234 Crainich et al. Apr 2009 A1
20090112537 Okumura Apr 2009 A1
20100010631 Otte et al. Jan 2010 A1
20100023024 Zeiner et al. Jan 2010 A1
20100030262 McLean et al. Feb 2010 A1
20100030263 Cheng et al. Feb 2010 A1
20100063351 Witzmann et al. Mar 2010 A1
20100063542 Burg et al. Mar 2010 A1
20100114162 Bojarski et al. May 2010 A1
20100191045 Gobron et al. Jul 2010 A1
20100240951 Catanese et al. Sep 2010 A1
20100256442 Ogdahl et al. Oct 2010 A1
20100261950 Lund et al. Oct 2010 A1
20100286106 Gat et al. Nov 2010 A1
20100286679 Hoey et al. Nov 2010 A1
20100286717 Heinrich et al. Nov 2010 A1
20100298948 Hoey et al. Nov 2010 A1
20110040312 Lamson et al. Feb 2011 A1
20110046648 Johnston et al. Feb 2011 A1
20110054493 McLean Mar 2011 A1
20110060349 Cheng et al. Mar 2011 A1
20110082471 Holcomb et al. Apr 2011 A1
20110105841 Kutikov et al. May 2011 A1
20110160747 McLean et al. Jun 2011 A1
20110166564 Merrick et al. Jul 2011 A1
20110172755 Nelson et al. Jul 2011 A1
20110190758 Lamson et al. Aug 2011 A1
20110218387 Lamson et al. Sep 2011 A1
20110245828 Baxter et al. Oct 2011 A1
20110276081 Kilemnik Nov 2011 A1
20120041533 Bertolino et al. Feb 2012 A1
20120041534 Clerc et al. Feb 2012 A1
20120083836 Shelton, IV Apr 2012 A1
20120245600 McLean et al. Sep 2012 A1
20120265006 Makower et al. Oct 2012 A1
20130096582 Cheng et al. Apr 2013 A1
20130211431 Wei et al. Aug 2013 A1
20130253574 Catanese et al. Sep 2013 A1
20130253662 Lamson et al. Sep 2013 A1
20130261383 Catanese et al. Oct 2013 A1
20130261665 Yeung et al. Oct 2013 A1
20130267772 Catanese et al. Oct 2013 A1
20130268001 Catanese et al. Oct 2013 A1
20130274799 Catanese et al. Oct 2013 A1
20130289342 Tong et al. Oct 2013 A1
20130296639 Lamson et al. Nov 2013 A1
20130296889 Tong et al. Nov 2013 A1
20130296935 McLean et al. Nov 2013 A1
20130325143 Lamson et al. Dec 2013 A1
20140005473 Catanese et al. Jan 2014 A1
20140005690 Catanese et al. Jan 2014 A1
20140031835 Viker et al. Jan 2014 A1
20140088587 Merrick et al. Mar 2014 A1
20140180067 Stigall et al. Jun 2014 A1
20140236230 Johnston et al. Aug 2014 A1
20140275756 Bender et al. Sep 2014 A1
20140296881 Ranucci et al. Oct 2014 A1
20140330290 Tong et al. Nov 2014 A1
20150025652 McLean et al. Jan 2015 A1
20150127050 Lamson et al. May 2015 A1
20150351743 Stiggelbout Dec 2015 A1
20160022265 Kawaura et al. Jan 2016 A1
20160045297 Siegel et al. Feb 2016 A1
20160095685 Vemuri et al. Apr 2016 A1
20160228107 Madsen et al. Aug 2016 A1
20170000598 Bachar Jan 2017 A1
20170035410 Catanese et al. Feb 2017 A1
20170135830 Harkin et al. May 2017 A1
20170156723 Keating et al. Jun 2017 A1
20180103945 Ciulla et al. Apr 2018 A1
20180318114 Huang et al. Nov 2018 A1
20190125334 Tong et al. May 2019 A1
20190298334 Catanese et al. Oct 2019 A1
20200038213 Bly et al. Feb 2020 A1
20200121442 Askeland Apr 2020 A1
20200170638 Roslin et al. Jun 2020 A1
20210145619 Bly et al. May 2021 A1
20210161641 Bachar Jun 2021 A1
20210161642 Jen et al. Jun 2021 A1
20210307641 Rumbles et al. Oct 2021 A1
20220000445 Datta et al. Jan 2022 A1
20220031303 Yarra et al. Feb 2022 A1
20220031358 Yarra et al. Feb 2022 A1
20220031389 Fischell et al. Feb 2022 A1
20220061834 Chung et al. Mar 2022 A1
20220125499 Hoey et al. Apr 2022 A1
20220133462 Kilemnik May 2022 A1
20220142464 Petroff et al. May 2022 A1
20220240925 Epstein et al. Aug 2022 A1
20220249219 Chung et al. Aug 2022 A1
20220265262 Melsheimer Aug 2022 A1
20220273918 Ghriallais et al. Sep 2022 A1
20220378577 Anderson et al. Dec 2022 A1
20220395363 Ghriallais et al. Dec 2022 A1
20230022482 Dhavale Jan 2023 A1
Foreign Referenced Citations (104)
Number Date Country
2477220 Nov 2007 CA
101795641 Aug 2010 CN
102112064 Jun 2014 CN
105852938 Aug 2016 CN
109009285 Dec 2018 CN
109675177 Apr 2019 CN
211156119 Aug 2020 CN
112891032 Jun 2021 CN
216221843 Apr 2022 CN
10159470 Jun 2003 DE
102019101987 Jul 2020 DE
0246836 Dec 1991 EP
0464480 Jan 1992 EP
0632999 Jan 1995 EP
1016377 Jul 2000 EP
1482841 Dec 2004 EP
1082941 Mar 2005 EP
1006909 Jan 2007 EP
1852071 Nov 2007 EP
1584295 Feb 2008 EP
1884198 Feb 2008 EP
1884199 Feb 2008 EP
1887976 Feb 2008 EP
1670361 Apr 2008 EP
1962720 Sep 2008 EP
1331886 Dec 2008 EP
1482840 Dec 2008 EP
2164427 Mar 2010 EP
1484023 May 2011 EP
2345373 Jul 2011 EP
2345374 Jul 2011 EP
2600781 Jun 2013 EP
2658477 Nov 2013 EP
2049023 Dec 2014 EP
2344048 Sep 2016 EP
2111167 Nov 2018 EP
2339970 Nov 2018 EP
2658458 Feb 2020 EP
2750031 Dec 1997 FR
5836559 Mar 1983 JP
1984500876 May 1984 JP
09122134 May 1997 JP
2000140111 May 2000 JP
2001137254 May 2001 JP
2004344427 Dec 2004 JP
2009106755 May 2009 JP
2009521278 Jun 2009 JP
2011529745 Dec 2011 JP
2012143622 Aug 2012 JP
2023502729 Jan 2023 JP
101534820 Jul 2015 KR
2062121 Jun 1996 RU
2112571 Jun 1998 RU
2128012 Mar 1999 RU
2221501 Jan 2004 RU
825094 Apr 1981 SU
1983004285 Dec 1983 WO
1987001270 Mar 1987 WO
1991008708 Jun 1991 WO
1992010142 Jun 1992 WO
1993004727 Mar 1993 WO
1993015664 Aug 1993 WO
1995000818 Jan 1995 WO
2000040159 Jul 2000 WO
2001026588 Apr 2001 WO
2001028432 Apr 2001 WO
2001039671 Jun 2001 WO
2001049195 Jul 2001 WO
2001065997 Sep 2001 WO
2001095818 Dec 2001 WO
2002028289 Apr 2002 WO
2002030335 Apr 2002 WO
2002032321 Apr 2002 WO
2003039334 May 2003 WO
2003077772 Sep 2003 WO
2004000159 Dec 2003 WO
2004017845 Mar 2004 WO
2004019787 Mar 2004 WO
2004019788 Mar 2004 WO
2004030569 Apr 2004 WO
2004103189 Dec 2004 WO
2005034738 Apr 2005 WO
2005094447 Oct 2005 WO
2006127431 Nov 2006 WO
2007053516 May 2007 WO
2007064906 Jun 2007 WO
2007075981 Jul 2007 WO
2008006084 Jan 2008 WO
2008014191 Jan 2008 WO
2008043044 Apr 2008 WO
2008043917 Apr 2008 WO
2008097942 Aug 2008 WO
2009009617 Jan 2009 WO
2009135005 Nov 2009 WO
2010011832 Jan 2010 WO
2010014821 Feb 2010 WO
2010014825 Feb 2010 WO
2012018446 Feb 2012 WO
2012028843 Mar 2012 WO
2012091952 Jul 2012 WO
2012091954 Jul 2012 WO
2012091955 Jul 2012 WO
2012091956 Jul 2012 WO
2021190092 Sep 2021 WO
Non-Patent Literature Citations (26)
Entry
Singapore Written Opinion dated Jul. 5, 2022 in SG Patent Application No. 11202200716X.
Prosecution document: First Office Action dated Mar. 29, 2023, in U.S. Appl. No. 17/384,056.
First Office Action dated Nov. 19, 2021, in U.S. Appl. No. 17/384,014.
PCT International Search Report dated Nov. 11, 2021, in PCT/US2021/042902.
PCT Written Opinion dated Nov. 11, 2021, in PCT/US2021/042902.
Prosecution document: Response to first Office Action dated Feb. 10, 2022, in U.S. Appl. No. 17/384,014.
Bacharova, O.A., et al. “The Effect of Rhodiolae rosea Extract on Incidence Rate of Superficial Bladder Carcinoma Relapses”, Kozin 1995.
Berges, Richard, et al. “Alternative Minimalinvasive Therapien Beim Benignen Prostatasyndrom”, Medizin, Jg. 104, Heft 37, Sep. 14, 2007.
Borzhievski, et al., “Tactics of the Surgical Treatment of Patients With Prostatic Adenoma and Acute Urinary Retention,” Urologia Nefrol (Mosk), Jan.-Feb. 1987, (1):39-43.
Extended European Search Report dated Jan. 20, 2020 in EP Patent Application No. 19199026.6.
Hartung, Rudolf, et al. “Instrumentelle Therapie der benignen Prostatahyperplasie”, Medizin, Deutsches Arzteblatt 97, Heft 15, Apr. 14, 2000.
Hofner, Klaus, et al., “Operative Therapie des benignen Prostatasyndroms”, Medizin, Dtsch Arztebl, 2007; 104(36):A 2424-9.
Hubmann, R. “Geschichte der transurethralen Prostataeingriffe”, Geschichte der Medizin, Urologe [B], 2000, 40:152-160.
Jonas, U., et al., “Benigne Prostatahyperplasie”, Der Urologe 2006—[Sonderheft] 45:134-144.
Kruck, S., et al., “Aktuelle Therapiemoglichkeiten des Benignen Prostata-Syndroms”, J Urol Urogynakol, 2009; 16(1): 19-22.
Miyake, Osamu. “Medical Examination and Treatment for BPH,” Pharma Med, vol. 22, No. 3, 2004, p. 97-103.
Reich, O., et al., “Benignes Prostatasyndrom (BPS),” Der Urologe A Issue vol. 45, No. 6, Jun. 2006, p. 769-782.
Schauer, P., et al. “New applications for endoscopy: the emerging field of endoluminal and transgastric bariatric surgery”, Surgical Endoscopy, (Apr. 24, 2006), 10 pgs.
Sharp, Howard T., M.D., et al. “Instruments and Methods—The 4-S Modification of the Roeder Knot: How to Tie It”, Obstetrics & Gynecology, p. 1004-1006, vol. 90, No. 6, Dec. 1997.
Takashi, Daito. “Low-Invasive Treatment for BPH”, Medico vol. 34, No. 10, p. 366-369, 2000.
Teruhisa, Ohashi. “Urinary Dysfunction by Lower Urinary Tract Obstraction in Male”, Pharma Medica, vol. 8, No. 8, p. 35-39, 1990.
Tomohiko, Koyanagi, et al., “Surgery View of 21st Century,” Urological Surgery, vol. 84, No. 1, p. 47-53, 2001.
Trapeznikov, et al., “New Technologies in the Treatment of Benign Prostatic Hyperplasia”, Urologia Nefrol (Mosk), Jul.-Aug. 1996, (4):41-47.
Yeung, Jeff. “Treating Urinary Stress Incontenance Without Incision with Endoscopic Suture Anchor & Approximating Device,” Aleeva Medical, Inc., 2007.
Prosecution document: Response to First Office Action filed Jun. 29, 2023, in U.S. Appl. No. 17/384,056.
Prosecution document: Final Office Action dated Jul. 28, 2023, in U.S. Appl. No. 17/384,056.
Related Publications (1)
Number Date Country
20220031357 A1 Feb 2022 US
Provisional Applications (1)
Number Date Country
63060442 Aug 2020 US